Combining VEGF receptor inhibitors and angiotensin-(1-7) to target renal cell carcinoma

Area of Science:

• Oncology
• Pharmacology

Background:

• Metastatic kidney cancer often develops resistance to vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs).
• This resistance limits the long-term efficacy of standard treatments.

Purpose of the Study:

• To investigate the potential of angiotensin-(1-7) peptide as a therapeutic agent to overcome or delay VEGFR TKI resistance in metastatic kidney cancer.

Main Methods:

• The study likely involved preclinical models or patient-derived samples to assess the effects of VEGFR TKIs with and without angiotensin-(1-7).
• Key endpoints would include tumor growth, markers of resistance, and survival.

Main Results:

• Addition of angiotensin-(1-7) peptide demonstrated a capacity to delay the onset of resistance to VEGFR TKIs.
• This suggests a novel therapeutic strategy for managing advanced kidney cancer.

Conclusions:

• Angiotensin-(1-7) peptide represents a promising therapeutic addition to combat VEGFR TKI resistance in metastatic kidney cancer.
• Further clinical investigation is warranted to validate these findings.